Theriva Biologics Inc (TOVX)

$0.25 +0.00 (2.02%)
Market Cap 8.35M
Revenue (ttm) 0.00
Net Income (ttm) -23.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.11
Volume 344,400
Avg Vol 1,317,070
Day's Range N/A - N/A
Shares Out 33.74M
Stochastic %K 36%
Beta 1.14
Analysts Strong Sell
Price Target $2.50

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for trea...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 417 4364
Address:
9605 Medical Center Drive, Suite 270, Rockville, United States
StockBoySam
StockBoySam Sep. 13 at 1:15 PM
$TOVX Information https://warrantwire.com/TOVX
0 · Reply
ValuePrince
ValuePrince Sep. 13 at 1:48 AM
$TOVX /
0 · Reply
dogood
dogood Sep. 11 at 1:37 AM
$OLB will you hit .50 tomorrow.. i am waiting for $ENSC $1.5 $TOVX $1 $OLB .50+
0 · Reply
dogood
dogood Sep. 10 at 10:52 PM
$OLB tomorrow would be nice if these two stocks close at this price in an hr. I wish and pray for it $OLB .35 $PRZO .88 $ENSC .50 $TOVX .27
0 · Reply
exwallstcfo
exwallstcfo Sep. 10 at 7:45 PM
$TOVX interesting read https://warrantwire.com/therivabiologics/tovx
0 · Reply
dogood
dogood Sep. 10 at 12:06 PM
$OLB all are good stocks but stock shorters greediness not letting go above $1 $TOVX $ENSC $OLB $PRZO $WHLR
0 · Reply
dogood
dogood Sep. 10 at 12:02 AM
$TOVX can this hit long pending $2
0 · Reply
dogood
dogood Sep. 8 at 11:54 PM
$TOVX will this get to $1?
0 · Reply
RealFValue
RealFValue Sep. 8 at 6:52 PM
$TOVX scam coin
0 · Reply
OutLawTrades
OutLawTrades Sep. 3 at 8:01 PM
$TOVX Fish on Let’s Go
0 · Reply
Latest News on TOVX
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Aug 11, 2026, 8:00 AM EDT - 4 weeks ago

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics Earnings release: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 4 weeks ago

Theriva Biologics Earnings release: Q2 2026

Theriva Biologics Quarterly report: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 4 weeks ago

Theriva Biologics Quarterly report: Q2 2026

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain

2026-07-07T12:25:34.000Z - 2 months ago

Theriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Jul 7, 2026, 8:00 AM EDT - 2 months ago

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Theriva Biologics Proxy statement: Proxy filing

Theriva Biologics Proxy statement: Proxy filing

Jun 18, 2026, 8:00 AM EDT - 2 months ago

Theriva Biologics Proxy statement: Proxy filing

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

Jun 11, 2026, 8:00 AM EDT - 3 months ago

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

Theriva Biologics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 4 months ago

Theriva Biologics Slides: Corporate presentation

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

May 5, 2026, 4:30 PM EDT - 4 months ago

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics Earnings release: Q1 2026

May 5, 2026, 4:00 PM EDT - 4 months ago

Theriva Biologics Earnings release: Q1 2026

Theriva Biologics Quarterly report: Q1 2026

May 5, 2026, 4:00 PM EDT - 4 months ago

Theriva Biologics Quarterly report: Q1 2026

Theriva Biologics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Theriva Biologics Proxy statement: Proxy filing

Theriva Biologics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Theriva Biologics Proxy statement: Proxy filing

Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial

2026-04-17T20:11:52.000Z - 4 months ago

Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Apr 17, 2026, 4:05 PM EDT - 4 months ago

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path

2026-03-31T13:48:40.000Z - 5 months ago

Theriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path

Theriva Biologics upgraded to Buy from Hold at Maxim

2026-03-31T11:54:39.000Z - 5 months ago

Theriva Biologics upgraded to Buy from Hold at Maxim

Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA

2026-03-23T12:10:57.000Z - 5 months ago

Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA

Theriva Biologics Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics price target lowered to $4 from $7 at Alliance Global

2026-03-13T13:38:56.000Z - 6 months ago

Theriva Biologics price target lowered to $4 from $7 at Alliance Global

Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year

2026-03-12T12:07:24.000Z - 6 months ago

Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year

Theriva Biologics sees cash runway into 1Q27

2026-03-12T12:05:50.000Z - 6 months ago

Theriva Biologics sees cash runway into 1Q27

Theriva Biologics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Theriva Biologics Earnings release: Q4 2025

Theriva Biologics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Theriva Biologics Annual report: Q4 2025

Theriva Biologics Proxy statement: Proxy Filing

Mar 4, 2026, 7:00 AM EST - 6 months ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

2026-02-18T13:16:44.000Z - 6 months ago

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

Theriva Biologics Proxy statement: Proxy Filing

Jan 5, 2026, 7:00 AM EST - 8 months ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design

2025-12-29T13:05:25.000Z - 8 months ago

Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Dec 29, 2025, 8:00 AM EST - 8 months ago

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Proxy statement: Proxy Filing

Dec 23, 2025, 7:00 AM EST - 8 months ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year

2025-11-12T13:16:18.000Z - 10 months ago

Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year

Theriva Biologics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Theriva Biologics Quarterly report: Q3 2025

Theriva Biologics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Theriva Biologics Earnings release: Q3 2025

Theriva Biologics Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 10 months ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics Proxy statement: Proxy Filing

Nov 10, 2025, 7:00 AM EST - 10 months ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics files to sell 16.18M shares of common stock for holders

2025-11-07T21:40:16.000Z - 10 months ago

Theriva Biologics files to sell 16.18M shares of common stock for holders

Theriva Biologics Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

Theriva Biologics Registration statement: Registration Filing

Theriva Biologics Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 10 months ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics sees no material development to account for unusual trading

2025-10-24T18:40:09.000Z - 10 months ago

Theriva Biologics sees no material development to account for unusual trading

Theriva Biologics Provides Response to Unusual Market Action

Oct 24, 2025, 2:31 PM EDT - 10 months ago

Theriva Biologics Provides Response to Unusual Market Action

Theriva Biologics announces warrant inducement transaction for $4M in proceeds

2025-10-16T12:20:41.000Z - 11 months ago

Theriva Biologics announces warrant inducement transaction for $4M in proceeds

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Oct 16, 2025, 8:11 AM EDT - 11 months ago

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year

2025-08-11T12:12:44.000Z - 1 year ago

Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year

Theriva Biologics sees cash runway into 1Q26

2025-08-11T12:12:22.000Z - 1 year ago

Theriva Biologics sees cash runway into 1Q26

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Theriva Biologics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Quarterly report: Q2 2025

Theriva Biologics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Earnings release: Q2 2025

Theriva Biologics Proxy statement: Proxy Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics announces presentation of data from VCN-01 Phase 1 trial

2025-05-27T12:20:41.000Z - 1 year ago

Theriva Biologics announces presentation of data from VCN-01 Phase 1 trial

Theriva Biologics reports Q1 EPS ($1.55) vs ($7.53) last year

2025-05-14T12:52:55.000Z - 1 year ago

Theriva Biologics reports Q1 EPS ($1.55) vs ($7.53) last year

Theriva Biologics sees cash runway into 1Q26

2025-05-14T12:52:08.000Z - 1 year ago

Theriva Biologics sees cash runway into 1Q26

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 14, 2025, 8:40 AM EDT - 1 year ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Theriva Biologics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Quarterly report: Q1 2025

Theriva Biologics Earnings release: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Earnings release: Q1 2025

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 8, 2025, 4:30 PM EDT - 1 year ago

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

May 7, 2025, 9:17 AM EDT - 1 year ago

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics Registration statement: Registration Filing

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 19, 2025, 8:10 AM EDT - 1 year ago

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Mar 6, 2025, 4:10 PM EST - 1 year ago

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva Biologics Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Theriva Biologics Earnings release: Q4 2024

Theriva Biologics Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Theriva Biologics Annual report: Q4 2024

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Mar 5, 2025, 4:05 PM EST - 1 year ago

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva Biologics Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Theriva Biologics Registration statement: Registration Filing

Dec 10, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Dec 5, 2024, 8:00 AM EST - 1 year ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Quarterly report: Q3 2024

Theriva Biologics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Earnings release: Q3 2024

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics Proxy statement: Proxy Filing

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Sep 26, 2024, 9:06 PM EDT - 1 year ago

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics Registration statement: Registration Filing

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Theriva Biologics Proxy statement: Proxy Filing

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Theriva Biologics Registration statement: Registration Filing

Sep 11, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing

Theriva Biologics Registration statement: Registration Filing

Sep 10, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing

Theriva Biologics Announces Reverse Stock Split

Aug 16, 2024, 4:05 PM EDT - 2 years ago

Theriva Biologics Announces Reverse Stock Split

Theriva Biologics Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Quarterly report: Q2 2024

Theriva Biologics Earnings release: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q2 2024

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Jul 31, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 23, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 14, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Theriva Biologics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva Biologics Quarterly report: Q1 2024

Theriva Biologics Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q1 2024

Theriva Biologics Registration statement: Registration Filing

May 2, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

Apr 25, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 22, 2024, 4:35 PM EDT - 2 years ago

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Theriva Biologics Earnings Call Transcript: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Earnings Call Transcript: Q4 2023

Theriva Biologics Annual report: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Annual report: Q4 2023

Theriva Biologics Earnings release: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q4 2023

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Mar 25, 2024, 7:30 AM EDT - 2 years ago

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Feb 7, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Jan 16, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Theriva Biologics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Theriva Biologics Earnings Call Transcript: Q3 2023

Theriva Biologics Quarterly report: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Theriva Biologics Quarterly report: Q3 2023

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Theriva™ Biologics to Participate in the BIO-Europe Conference

Nov 2, 2023, 4:15 PM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Conference

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics to Participate in the Emerging Growth Conference

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Participate in the Emerging Growth Conference

Theriva Biologics Proxy statement: Proxy Filing

Aug 16, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics Proxy statement: Proxy Filing

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Proxy statement: Proxy Filing

Theriva Biologics Earnings Call Transcript: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q2 2023

Theriva Biologics Quarterly report: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Quarterly report: Q2 2023

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 8, 2023, 8:00 AM EDT - 3 years ago

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Aug 2, 2023, 7:00 AM EDT - 3 years ago

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Aug 1, 2023, 4:05 PM EDT - 3 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

Jun 27, 2023, 4:10 PM EDT - 3 years ago

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 23, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

Theriva Biologics Earnings Call Transcript: Q1 2023

May 11, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q1 2023

Theriva Biologics Quarterly report: Q1 2023

May 11, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Quarterly report: Q1 2023

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 11, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

StockBoySam
StockBoySam Sep. 13 at 1:15 PM
$TOVX Information https://warrantwire.com/TOVX
0 · Reply
ValuePrince
ValuePrince Sep. 13 at 1:48 AM
$TOVX /
0 · Reply
dogood
dogood Sep. 11 at 1:37 AM
$OLB will you hit .50 tomorrow.. i am waiting for $ENSC $1.5 $TOVX $1 $OLB .50+
0 · Reply
dogood
dogood Sep. 10 at 10:52 PM
$OLB tomorrow would be nice if these two stocks close at this price in an hr. I wish and pray for it $OLB .35 $PRZO .88 $ENSC .50 $TOVX .27
0 · Reply
exwallstcfo
exwallstcfo Sep. 10 at 7:45 PM
$TOVX interesting read https://warrantwire.com/therivabiologics/tovx
0 · Reply
dogood
dogood Sep. 10 at 12:06 PM
$OLB all are good stocks but stock shorters greediness not letting go above $1 $TOVX $ENSC $OLB $PRZO $WHLR
0 · Reply
dogood
dogood Sep. 10 at 12:02 AM
$TOVX can this hit long pending $2
0 · Reply
dogood
dogood Sep. 8 at 11:54 PM
$TOVX will this get to $1?
0 · Reply
RealFValue
RealFValue Sep. 8 at 6:52 PM
$TOVX scam coin
0 · Reply
OutLawTrades
OutLawTrades Sep. 3 at 8:01 PM
$TOVX Fish on Let’s Go
0 · Reply
AtariLynx
AtariLynx Sep. 3 at 6:41 PM
$TOVX hi guys, I’m new here. Will be there a reverse split in the next months?
0 · Reply
dogood
dogood Sep. 3 at 2:54 PM
$TOVX this is very painful waiting for $1.5 many years
0 · Reply
gan23
gan23 Sep. 2 at 8:49 PM
$TOVX This one has been YoYoing between 0.23-0.25 for days. Something got to give - just a cpl of pennies more for me to be in the green
0 · Reply
RealFValue
RealFValue Sep. 2 at 4:57 AM
$TOVX scam coin
0 · Reply
ZACHSPIZZA
ZACHSPIZZA Sep. 1 at 7:47 PM
$TOVX only green thing out there haha
0 · Reply
Waham
Waham Sep. 1 at 5:21 PM
$TOVX tick tack 😗
0 · Reply
dogood
dogood Sep. 1 at 12:21 PM
$TOVX hourly and daily candles are bullish , will it break .50 today ?
1 · Reply
dogood
dogood Sep. 1 at 11:52 AM
$TOVX come on brother will you have news today and run to $1
0 · Reply
dogood
dogood Aug. 31 at 3:33 PM
$TOVX one push breaks .30 we could hit .60 faster
0 · Reply
shebo
shebo Aug. 31 at 3:17 PM
$TOVX Next runner!!
0 · Reply
Lovelife68
Lovelife68 Aug. 31 at 1:42 PM
$TOVX Remove Margin from your accounts! That way they can’t borrow your shares to short!
0 · Reply
ZACHSPIZZA
ZACHSPIZZA Aug. 31 at 12:53 PM
$TOVX waiting. Forever lol
2 · Reply